<DOC>
	<DOCNO>NCT02963701</DOCNO>
	<brief_summary>The objective current study demonstrate bioequivalence fix dose combination tablet contain ibuprofen 400 mg pseudoephedrine-HCl 60 mg ( Test ) two tablet RhinAdvil® ( Reference ) fix dose combination tablet contain ibuprofen 200 mg pseudoephedrine-HCl 30 mg follow orally administration respect analytes , ibuprofen pseudoephedrine-HCl .</brief_summary>
	<brief_title>Bioequivalence Fixed Dose Combination Tablet Containing 400 mg Ibuprofen 60 mg Pseudoephedrine-HCl Compared Two Film Coated Fixed Dose Combination Tablets RhinAdvil ( R ) ( 200 mg Ibuprofen 30 mg Pseudoephedrine-HCl ) Administered Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Inclusion criterion : Healthy male females accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age ≥21 ≤50 year Minimum weight 50kg male female Body Mass Index ≥18.5 ≤29.9 kg/m2 Signed date write informed consent accordance Good Clinical Practice ( GCP ) local legislation prior admission trial Male female patient . Women childbearing potential1 must ready able use highly effective method birth control per International Committee Harmonisation ( ICH ) M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly e.g . implant , injectables , combine hormonal contraceptive , intrauterine device , surgical sterilisation ( include hysterectomy ) . In addition , also barrier method ( e.g . male condom ) require , female surgically sterilise . A list contraception method meet criterion provide patient information . Abstaining sexual activity ( usual lifestyle subject ) consider acceptable method birth control . Exclusion criterion : Any find medical examination ( include Blood Pressure , Pulse Rate Electrocardiogram ) deviate normal clinical relevance discretion investigator Any evidence clinically relevant concomitant disease Any relevant Gastrointestinal ( e.g . ulcera , hernia , bleeding spasm ) , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Any relevant surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder relevant neurological disorder discretion investigator History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy drug excipients ) judge clinically relevant investigator Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives respective drug prior first drug administration Use drug might reasonably influence result trial base knowledge time protocol preparation within 14 day prior randomisation Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day judge investigator Alcohol abuse ( average consumption 2 unit per day females 3 unit per day male ) Drug abuse Blood donation ( 100 mL within four week prior administration trial drug study ) Excessive physical activity within 1 week prior randomisation trial Any laboratory value outside reference range clinical relevance discretion investigator Inability comply dietary regimen study centre Unwilling avoid excessive sunlight exposure Use drug might reasonably influence result trial prolong QT/QTc interval within 14 day prior administration trial , CYP2C8 substrates amiodarone , amodiaquine , paclitaxel , rosiglitazone , pioglitazone repaglinide CYP2C9 warfarin , tolbutamide , phenytoin , losartan , acenocoumarol within 1 month six halflives ( whichever great ) A marked baseline prolongation QTc B interval ( e.g. , repeated demonstration QTc B interval &gt; 450 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome ) Special exclusion criterion : Subjects history bronchospasm , rhinitis urticaria associate Nonsteroidal antiinflammatory drug ( NSAID ) Asthma Risk manifest narrowangle glaucoma Risk urinary retention due urethroprostatic disease / prostatic enlargement Subjects rare hereditary problem fructose intolerance , glucosegalactose malabsorption sucrase isomaltase deficiency Regular treatment systemically available medication ( except hormonal contraceptive hormonal replacement therapy e.g . estrogen , Lthyroxine ) Subjects , report frequent occurrence migraine attack For female subject childbearing potential : Positive pregnancy test , pregnancy plan become pregnant study within 2 month study completion No adequate contraception study include three month first dose 2 month study completion . Lactation Administrative reason : Subjects suspect know follow instruction Subjects unable understand write verbal instruction , particular regard risk inconvenience expose participation study The exclusion criterion choose assure subject specific risk administration investigational medicinal product subject condition , may impact pharmacokinetic parameter , include</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>